TY - JOUR
T1 - Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine
AU - Boyette-Davis, Jessica A.
AU - Cata, Juan P.
AU - Driver, Larry C.
AU - Novy, Diane M.
AU - Bruel, Brian M.
AU - Mooring, Deidre L.
AU - Wendelschafer-Crabb, Gwen
AU - Kennedy, William R.
AU - Dougherty, Patrick M.
N1 - Funding Information:
Acknowledgments The work was supported by grants NS046606 and CA124787 and by a gift from the Peggy and Avinash Ahuja Center of Excellence in Pain Research and Treatment. The authors would like to thank Dr. Allen Burton and Dr. Sergio Giralt for their assistance with data collection.
PY - 2013/3
Y1 - 2013/3
N2 - Purpose: Chemoneuropathy remains a painful, burdensome complication of cancer treatment for patients receiving a range of chemotherapeutics, yet the cause and persistence of this condition are not fully documented. This study was designed to quantify the longevity of and contributions to neuropathy following treatment with the plant alkaloids paclitaxel and vincristine. Methods: Quantitative sensory testing was conducted approximately 18 months apart on 14 patients, seven of which had been treated with paclitaxel and seven with vincristine and compared to data from 18 healthy control subjects. In addition, skin biopsies were obtained to investigate changes in the density of Meissner's corpuscles and epidermal nerve fibers (ENFs), the loss of which is thought to contribute to multiple forms of neuropathy. Results: Impairments in motor skills, as measured by a grooved peg-board, were found. Deficits in touch detection were observed using von Frey monofilaments, as were changes in sharpness detection using a weighted needle device. Using a Peltier device, warmth and heat detection were impaired. These deficits were consistent across time. Remarkably, the average length of time patients reported painful neuropathy was over four and a half years. Skin biopsies were found to be deficient in Meissner's corpuscles and ENFs. Conclusions: The combination of widespread deficits in sensory testing and decreases in skin innervation for cancer patients receiving paclitaxel or vincristine document a persistent polyneuropathy which severely impacts these patients. Decreases in Meissner's corpuscles and ENFs indicate a possible mechanism for the neuropathy.
AB - Purpose: Chemoneuropathy remains a painful, burdensome complication of cancer treatment for patients receiving a range of chemotherapeutics, yet the cause and persistence of this condition are not fully documented. This study was designed to quantify the longevity of and contributions to neuropathy following treatment with the plant alkaloids paclitaxel and vincristine. Methods: Quantitative sensory testing was conducted approximately 18 months apart on 14 patients, seven of which had been treated with paclitaxel and seven with vincristine and compared to data from 18 healthy control subjects. In addition, skin biopsies were obtained to investigate changes in the density of Meissner's corpuscles and epidermal nerve fibers (ENFs), the loss of which is thought to contribute to multiple forms of neuropathy. Results: Impairments in motor skills, as measured by a grooved peg-board, were found. Deficits in touch detection were observed using von Frey monofilaments, as were changes in sharpness detection using a weighted needle device. Using a Peltier device, warmth and heat detection were impaired. These deficits were consistent across time. Remarkably, the average length of time patients reported painful neuropathy was over four and a half years. Skin biopsies were found to be deficient in Meissner's corpuscles and ENFs. Conclusions: The combination of widespread deficits in sensory testing and decreases in skin innervation for cancer patients receiving paclitaxel or vincristine document a persistent polyneuropathy which severely impacts these patients. Decreases in Meissner's corpuscles and ENFs indicate a possible mechanism for the neuropathy.
KW - Chemoneuropathy
KW - Epidermal nerve fiber
KW - Meissner's corpuscles
KW - Paclitaxel
KW - Vincristine
UR - http://www.scopus.com/inward/record.url?scp=84875819005&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875819005&partnerID=8YFLogxK
U2 - 10.1007/s00280-012-2047-z
DO - 10.1007/s00280-012-2047-z
M3 - Article
C2 - 23228992
AN - SCOPUS:84875819005
SN - 0344-5704
VL - 71
SP - 619
EP - 626
JO - Cancer chemotherapy and pharmacology
JF - Cancer chemotherapy and pharmacology
IS - 3
ER -